Simon McNamara

422 total citations
20 papers, 154 citations indexed

About

Simon McNamara is a scholar working on Hematology, Economics and Econometrics and Oncology. According to data from OpenAlex, Simon McNamara has authored 20 papers receiving a total of 154 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 9 papers in Economics and Econometrics and 7 papers in Oncology. Recurrent topics in Simon McNamara's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Multiple Myeloma Research and Treatments (9 papers) and Global Health Care Issues (4 papers). Simon McNamara is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Multiple Myeloma Research and Treatments (9 papers) and Global Health Care Issues (4 papers). Simon McNamara collaborates with scholars based in United Kingdom, United States and Spain. Simon McNamara's co-authors include John Holmes, Nils Gutacker, Aki Tsuchiya, P. Schneider, James Love-Koh, Tim Doran, Petra Meier, Helen M. Johnson, Neil Roskell and Dawn Lee and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Simon McNamara

16 papers receiving 152 citations

Peers

Simon McNamara

GHP

ONCOL

HEALT

EPIDE

Angela Cairns United Kingdom

Joe Varghese India

Han‐I Wang United Kingdom

Margo Michaels United States

Elle Pope United States

Florence Francis-Oliviero France

Juan Carlos Rejón-Parrilla United Kingdom

Suman Pramanik India

Judith Petersen United States

Shitong Xie China

Angela Cairns United Kingdom

Simon McNamara

41 ×0.7

GHP

30 ×0.5

12 ×0.4

ONCOL

46 ×1.6

HEALT

15 ×0.8

EPIDE

Citations per year, relative to Simon McNamara Simon McNamara (= 1×) peers Angela Cairns

Countries citing papers authored by Simon McNamara

Since Specialization

Citations

This map shows the geographic impact of Simon McNamara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon McNamara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon McNamara more than expected).

Fields of papers citing papers by Simon McNamara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon McNamara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon McNamara. The network helps show where Simon McNamara may publish in the future.

Co-authorship network of co-authors of Simon McNamara

This figure shows the co-authorship network connecting the top 25 collaborators of Simon McNamara. A scholar is included among the top collaborators of Simon McNamara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon McNamara. Simon McNamara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Richter, Joshua, Ajay K. Nooka, Paula Rodríguez‐Otero, et al.. (2025). Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis. American Journal of Hematology. 100(6). 998–1009. 1 indexed citations

Boytsov, Natalie, et al.. (2025). Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma. Future Oncology. 21(13). 1663–1673.

Gay, Francesca, Elena Zamagni, Craig E. Cole, et al.. (2025). Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review. Frontiers in Oncology. 15. 1550644–1550644.

McNamara, Simon, et al.. (2025). Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey. Future Oncology. 21(6). 681–690.

Iida, Shinsuke, Yevgeniy Samyshkin, Chi‐Chang Chen, et al.. (2025). Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis. PLoS ONE. 20(1). e0315932–e0315932. 2 indexed citations

Pompilus, Farrah, et al.. (2024). The Impact of Patient-Reported Adverse Events on Quality of Life: An Analysis of the Dreamm-7 and Dreamm-8 Randomized Controlled Trials. Blood. 144(Supplement 1). 3358–3358. 3 indexed citations

Hungria, Vânia, Paweł Robak, Marek Hus, et al.. (2024). Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S242–S242. 1 indexed citations

Hungria, Vânia, Paweł Robak, Marek Hus, et al.. (2024). Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7543–7543. 1 indexed citations

Weisel, Katja, et al.. (2024). Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence. British Journal of Haematology. 205(3). 780–797. 9 indexed citations

10.

Gay, Francesca, et al.. (2024). P-362 A Real-World Study to Assess Treatment Patterns and Outcomes of Patients (pts) with 2L+ Relapsed or Refractory Multiple Myeloma in Italy, Germany, and the United Kingdom. Clinical Lymphoma Myeloma & Leukemia. 24. S242–S242. 2 indexed citations

11.

Love-Koh, James, P. Schneider, Simon McNamara, Tim Doran, & Nils Gutacker. (2023). Decomposition of Quality-Adjusted Life Expectancy Inequalities by Mortality and Health-Related Quality of Life Dimensions. PharmacoEconomics. 41(7). 831–841. 11 indexed citations

12.

Lee, Dawn & Simon McNamara. (2023). Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality Into Cost-Effectiveness Analysis. Value in Health. 26(8). 1145–1150.

13.

Schneider, P., James Love-Koh, Simon McNamara, Tim Doran, & Nils Gutacker. (2022). Socioeconomic inequalities in HRQoL in England: an age-sex stratified analysis. Health and Quality of Life Outcomes. 20(1). 121–121. 11 indexed citations

14.

McNamara, Simon, P. Schneider, James Love-Koh, Tim Doran, & Nils Gutacker. (2022). Quality-Adjusted Life Expectancy Norms for the English Population. Value in Health. 26(2). 163–169. 34 indexed citations

15.

McNamara, Simon, Aki Tsuchiya, & John Holmes. (2020). Does the UK-public's aversion to inequalities in health differ by group-labelling and health-gain type? A choice-experiment. Social Science & Medicine. 269. 113573–113573. 11 indexed citations

16.

Holmes, John, et al.. (2020). Drinking contexts and their association with acute alcohol‐related harm: A systematic review of event‐level studies on adults' drinking occasions. Drug and Alcohol Review. 39(4). 309–320. 18 indexed citations

17.

McNamara, Simon, et al.. (2019). How averse are the UK general public to inequalities in health between socioeconomic groups? A systematic review. The European Journal of Health Economics. 21(2). 275–285. 31 indexed citations

18.

Lee, Dawn, Javier Sabater, Helen M. Johnson, et al.. (2018). Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England. PharmacoEconomics - Open. 3(1). 43–54. 17 indexed citations

19.

McNamara, Simon, et al.. (2014). Testing The Utility Of The Nhs's Systemic Anti-Cancer Therapy Data Set For Multi-Indication Pricing. Value in Health. 17(7). A659–A659. 1 indexed citations

20.

McNamara, Simon, et al.. (2010). PCN97 A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB + ANASTROZOLE COMPARED TO LAPATINIB + LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS). Value in Health. 13(7). A270–A270. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact